Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis

Annals of Surgical Oncology

Volumn 15, Issue 2, 2008, Pages 535-541

  Ceelen, Wim P ^a   Peeters, Marc ^a   Houtmeyers, Philippe ^a   Breusegem, Christophe ^a   De Somer, Filip ^a   Pattyn, Piet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemoperfusion; Chemotherapy; HIPEC; Oxaliplatin; Peritoneal carcinomatosis

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; ELECTROLYTE; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ANALYTIC METHOD; ANASTOMOTIC LEAK; ARTICLE; BLADDER LEAK; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERTHERMIC INTRAPERITONEAL CHEMOPERFUSION; HYPONATREMIA; ILEUS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; METABOLIC ACIDOSIS; METABOLIC PARAMETERS; MORBIDITY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PLEURA EFFUSION; PNEUMONIA; STOMACH PERFORATION; STOMACH ULCER; SURGICAL MORTALITY; URINARY TRACT INFECTION; WOUND INFECTION; AGED; BLOOD; DRUG EFFECT; GASTROINTESTINAL TUMOR; HYPERTHERMIC THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; LENGTH OF STAY; LIVER; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; REGIONAL PERFUSION;

AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; LENGTH OF STAY; LIVER; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 40649114011     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9648-5     Document Type: Article

References (27)

1. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34-43
2. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 2005; 288:F433-F42
3. Tannock IF, Lee CM, Tunggal JK, et al. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002; 8:878-84
4. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21:3737-43
5. Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24:4011-9
6. van Ruth S, Mathot RAA, Sparidans RW, et al. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokin 2004; 43:131-43
7. Zeamari S, Floot B, Van der Vange N, et al. Pharmacokinetics and pharmacodynamics of cisplatin after Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC). Anticancer Res 2003; 23:1643-8
8. Los G, Vanvugt MJH, Pinedo HM. Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994; 69:235-41
9. Chau I, Cunningham D. Adjuvant therapy in colon cancer - what, when and how? Ann Oncol 2006; 17:1347-59
10. Elkas JC, Winter WE, Chernofsky MR, et al. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 2007; 104:422-7
11. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22:658-63
12. Fennell DA, Steele JPC, Shamash J, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005; 47:277-81
13. Rietbroek RC, vandeVaart PJM, Haveman J, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997; 123:6-12
14. Pestieau SR, Belliveau JF, Griffin H, et al. Pharmacokinetics of intraperitoneal oxaliplatin: Experimental studies. J Surg Oncol 2001; 76:106-14
15. Elias D, Bonnay A, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002; 13:267-72
16. Jerremalm E, Hedeland M, Wallin I, et al. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004; 21:891-4
17. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460-6
18. Arotcarena R, Cales V, Berthelemy P, et al. Severe sinusoidal lesions: A serious and overlooked complication of oxaliplatin-containing chemotherapy? Gastroenterol Clin Biol 2006; 30:1313-6
19. Sugarbaker PH. Peritonectomy Procedures. Ann Surg 1995; 221:29-42
20. Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the Coliseum technique. Ann Surg Oncol 1999; 6:790-6
21. Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol 2004; 22:543S
22. Harnett P, Buck M, Beale P, et al. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: An Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer 2007; 17:359-66
23. Ceelen WP, Pahlman L, Mahteme H. Pharmacodynamic aspects of Intraperitoneal Cytotoxic therapy. In: Ceelen WP (ed) Peritoneal carcinomatosis: A multidisciplinary approach. New York, Springer; 2007. pp 195-214
24. Elias D, El Otmany A, Bonnay M, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002; 63:346-52
25. Reed E. Cisplatin, Carboplatin, and Oxaliplatin. In: Chabner BA, Longo DL (eds) Cancer Chemotherapy & Biotherapy: Principles & Practices, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2006
26. Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274-86
27. Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000; 38:1-21